SCHEMBL1407157

SCHEMBL1407157

Cc1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1cccc(Cl)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 13/20 0.68
NR1H3 Q13133 13/20 0.68
NR1I2 O75469 2/20 0.58
NR3C1 P04150 2/20 0.58
AR P10275 1/20 0.58
RXRA P19793 1/20 0.58
SLC16A3 O15427 1/20 0.38
SLC16A1 P53985 1/20 0.38
MCTS1 Q9ULC4 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
USP1 O94782 1/20 0.38
WDR48 Q8TAF3 1/20 0.38
P2RX7 Q99572 1/20 0.37
TP53 P04637 1/20 0.36
HSD11B1 P28845 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3856988 0.90 NR1H2 (0.80) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407274 0.90 NR1H2 (0.74) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407729 0.89 NR1H2 (0.80) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407832 0.89 NR1H2 (0.85) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL3857435 0.89 NR1H2 (0.73) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407341 0.87 NR1H2 (0.82) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407641 0.86 NR1H2 (0.86) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL3858532 0.84 NR1H2 (0.76) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1414296 0.83 NR1H2 (0.77) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407451 0.83 NR1H2 (0.68) NR1H2NR1H3NR1I2NR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
CN-101213194-A Indazoles useful in treating cardiovascular diseases WYETH CORP (US) 2008-07-02 CN claimed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP claimed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
CN-101213194-A Indazoles useful in treating cardiovascular diseases WYETH CORP (US) 2008-07-02 CN disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NR1I2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.